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Objective: Damaged articular cartilage does not heal well and can progress to osteoarthritis (OA). Human
bone marrow stem cells (BMC) are promising cells for articular cartilage repair, yet age- and sex-related
differences in their chondrogenesis have not been clearly identiﬁed. The purpose of this study is to test
whether the chondrogenic potential of human femoral BMC varies based on the sex and/or age of the
donor.
Design: BMC were isolated from 21 males (16–82 years old (y.o.)) and 20 females (20–77 y.o.) during
orthopaedic procedures. Cumulative population doubling (CPD) was measured and chondrogenesis was
evaluated by standard pellet culture assay in the presence or absence of transforming growth factor beta
1 (TGFb1). Pellet area was measured, and chondrogenic differentiation was determined by Toluidine blue
and Safranin O-Fast green histological grading using the Bern score and by glycosaminoglycan (GAG)
content.
Results: No difference in CPD was observed due to donor sex or age. The increase in pellet area with
addition of TGFb1 and the Bern score signiﬁcantly decreased with increasing donor age in male BMC, but
not in female BMC. A signiﬁcant reduction in GAG content per pellet was also observed with increasing
donor age in male BMC. This was not observed in female BMC.
Conclusions: This study showed an age-related decline in chondroid differentiation with TGFb1 stimu-
lation in male BMC, but not in female BMC. Understanding the mechanisms for these differences will
contribute to improved clinical use of autologous BMC for articular cartilage repair, and may lead to the
development of customized age- or sex-based treatments to delay or prevent the onset of OA.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Articular cartilage is an avascular tissue with limited intrinsic
healing capacity. Due to its inability to heal efﬁciently, focal carti-
lage injuries of the knee have an increased risk of progressing to
osteoarthritis (OA), a leading cause of disability1. Current treatment
modalities for articular cartilage repair include debridement,
osteochondral grafting, autologous chondrocyte implantation, and
microfracture2–4. While good to excellent clinical outcome scores
have been reported for each technique, the repaired cartilage is
biomechanically dissimilar to the surrounding native cartilage. This
can lead to degradation of the cartilage over time, which would set
the stage for the progression of OA. Thus, there is an urgent need to: Constance R. Chu, Director,
1, Pittsburgh, PA 15213, USA.
Research Society International. Puimprove articular cartilage repair, as it may delay, or even prevent
the onset of debilitating OA.
Microfracture is minimally invasive and the simplest of the
treatment techniques, as it involves penetrating the subchondral
bone to access repair cells from the bone marrow to inﬁltrate the
defect. Microfracture is, however, inconsistent4–6. A high degree of
variability in the amount of repair cartilage that ﬁlls the defect has
been reported, indicating that there may be a subpopulation of
patients that do not produce sufﬁcient repair tissue after micro-
fracture, leading to early failure4. Age has also been shown to affect
the clinical outcome of microfracture, with younger patients (<40
years old (y.o.)) showing better clinical outcome scores6. Since bone
marrow cells are the main repair cells recruited to the defect during
microfracture, it suggests an important and continued role for the
autogenous application of bone marrow stem cells (BMC) in artic-
ular cartilage repair. The variability seen in clinical outcome
measures suggests that BMC from different individuals could differ
in their capacity for chondrogenic differentiation.blished by Elsevier Ltd. All rights reserved.
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chondrogenic differentiation in vitro and in vivo7–15, few studies
have focused on comparing the chondrogenesis of BMC obtained
from a large number of individuals10,11,13. This comparison is
important to determine whether there is inherent variability at the
BMC level between individuals for chondrogenic repair, so that this
can be taken into account to develop efﬁcient BMC-based therapies
for articular cartilage repair. Since OA and injuries to articular
cartilage affect men and women of all ages, it is important to
determine whether the chondrogenic capacity of BMC differs based
on the sex and/or age of the donor. Sexual dimorphism in the
prevalence of OA has been reported, with women being diagnosed
more frequently than men, especially over the age of 501,16. Recent
studies have shown that cell sex can affect the differentiation
potential of both mouse and human progenitor cells17–20. As well,
aging has been shown to affect the osteogenic differentiation of
BMC21–23, although this was not conclusive in all studies24–26. Our
understanding of age- and sex-related differences in the chondro-
genic capacity of BMC has not been clearly deﬁned.
Cells isolated from bone marrow procured from the distal femur
are promising cells for articular cartilage repair, since this site could
be accessed as an autologous cell source, and these cells are similar
to those typically accessed during microfracture. Sex- and age-
related differences in the chondrogenic potential of femoral BMC
should be investigated to better develop BMC-based therapies for
articular cartilage repair. Such studiesmay also provide information
predictive of the outcome of microfracture, which may affect
patient selection and treatment chosen. For this reason, this study
was performed to test the hypothesis that the chondrogenic
potential of femoral human BMC varies based on the sex and/or age
of the donor. The ﬁndings obtained will be important to improving
articular cartilage repair, a strategy for potentially delaying the
onset of disabling OA.
Methods
Cell isolation and expansion
Femoral bone marrow reamings were obtained from males
and females undergoing orthopaedic surgery for fracture stabili-
zation or joint replacement according to an exempt IRB-approved
protocol at the University of Pittsburgh for discarded tissue. A
total of 41 femoral bone marrow reamings were obtained. The
donors ranged in age from 16 to 82 y.o. and included 21 males
(16–82, mean donor age 39 22) and 20 females (20–77, mean
donor age 5317). Freshly harvested bone marrow was minced,
washed with phosphate buffered saline (PBS; Invitrogen, Carls-
bad, CA, USA) and vortexed. The cell suspension was then passed
through a 70 mm cell strainer. Thirty-ﬁve ml of cell suspension
was loaded onto 15 ml Histopaque-1077 (Sigma–Aldrich, St.
Louis, Mo., USA) and fractioned by centrifugation (400g) for
30 min. Mononucleated cells were recovered from the
Histopaque-supernatant interface and cultured in Minimum
Essential Medium Alpha Medium (Invitrogen) supplemented
with 16.5% fetal bovine serum (FBS; lot selected for rapid growth
of BMC, Atlanta Biologicals, Lawrenceville, GA, USA), 1% peni-
cillin–streptomycin (Invitrogen), and 2 mM L-glutamine (Invi-
trogen). Cells were allowed to adhere for 5–7 days at 37C and 5%
CO2 before the ﬁrst medium change, which would remove any
non-adherent cells. Visible colonies were seen after 8–10 days of
initial plating and were detached from the tissue-culture plastic
with 0.25% trypsin (Invitrogen). BMC were replated at 100 cells/
cm2, trypsinized when they reached 70% conﬂuence, and either
used for experiments or replated at the same cell density for
further expansion. Medium was refreshed every 3–4 days.Cumulative population doublings (CPDs)
At passage 2, cells were placed in a T25-ﬂask at a density of
100 cells/cm2. After 7 days, cells were trypsinized, counted, and
replated at 100 cells/cm2. This was repeated until passage 8. Pop-
ulation doubling was calculated as the log2 (N/No), where No and N
are the number of cells originally plated and the number of cells at
the end of the expansion, respectively.Chondrogenic differentiation
Chondrogenesis was tested on BMC at passage 3 or 4 using
a previously described pellet culture assay8. A total of 2.5105 cells
were centrifuged at 500g for 5 min in 15-ml conical polypropylene
tubes. The cell pelletswere cultured in 0.5 ml chondrogenicmedium
(CM) that contained high-glucose Dulbecco’s Modiﬁed Eagle
Medium (Invitrogen) supplemented with 1% penicillin–strepto-
mycin,107 Mdexamethasone (Sigma–Aldrich), 50 mg/ml L-ascorbic
acid-2-phosphate (Sigma–Aldrich), 40 mg/ml proline (MP Biomedi-
cals, Solon, OH, USA), and 1% BDTM ITSþ Premix (Becton-Dickinson,
Franklin Lakes, NJ, USA), in the presence or absence of transforming
growth factor beta 1 (TGFb1) (10 ng/ml; R&D Systems, Minneapolis,
MN, USA). All pellets were incubated at 37C in 5% CO2 for 21 days,
and the CM was refreshed every 2–3 days.Area measurement of pellets
After 21 days of culture, macroscopic images of the pellets were
captured using a stereomicroscope (MVX-10 MacroView Systems,
Olympus, Japan) equipped with a DP71 camera (Olympus), and the
area was calculated using DP2-BSW software (Olympus). The
change in pellet area was calculated by dividing the area
measurement of pellets cultured in CMþ TGFb1 by that of pellets
cultured in CM only.Histological analysis
Pellets were ﬁxed in 10% buffered formalin followed by parafﬁn
embedding. Cross-sections (6 mm thick) were stained with Tolui-
dine blue for sulfated polysaccharides and Safranin O-Fast green for
sulfated glycosaminoglycans (GAG). Standard protocols for each of
these stains were followed. Images were captured with DP2-BSW
software (Olympus) using a Nikon TE-2000U Eclipse microscope
equipped with a DP71 camera (Olympus). Safranin O-Fast green
histology was graded by two blinded observers using the Bern
score27. Table I indicates the criteria used to grade Safranin O-Fast
green staining of pellets according to the Bern score.Biochemical analysis
Tomeasure total GAG content from BMC pellets, pellets cultured
for 21 days werewashed with PBS and each dry pellet was frozen at
80C until all pellets were ready to be assayed. Each frozen pellet
was placed in 0.2 ml papain buffer [50 mM phosphate buffer
(pH 6.5), 5 mM EDTA, 5 mM cysteine HCl and 0.5 mg/ml papain] in
a 60C water bath overnight. The pellets were then vortexed and
centrifuged for 5 min at 21,000g at room temperature. The
supernatant was transferred to a new tube, followed by GAG
quantiﬁcation. GAG was quantiﬁed using the standard dimethyl-
methylene blue (DMMB) assay28 with shark chondroitin-6-sulfate
(Sigma–Aldrich) as the standard.
Table I
The Bern score: for the evaluation of Safranin O-Fast green stained cartilagenous
pellet cultures (minimum score: 0; maximum score: 9)
Scoring categories Score
Category A: uniformity and darkness of Safranin
O-Fast green stain (10 objective)
No stain 0
Weak staining of poorly formed matrix 1
Moderately even staining 2
Even dark stain 3
Category B: distance between cells/amount of matrix
accumulated (20 objective)
High cell densities with no matrix in between
(no spacing between cells)
0
High cell densities with little matrix in between
(cells< 1 cell-size apart)
1
Moderate cell density with matrix
(cells approx. 1 cell-size apart)
2
Low cell density with moderate distance between cells
(>1 cell) and an extensive matrix
3
Category C: cellular morphologies represented (40 objective)
Condensed/necrotic/pycnotic bodies 0
Spindle/ﬁbrous 1
Mixed spindle/ﬁbrous with rounded chondrogenic morphology 2
Majority rounded/chondrogenic 3
Source: 27Grogan SP, et al. Tissue Eng 2006;12(8):2141–9.
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Data are reported as mean standard error of the mean (S.E.M.)
and analyzed using SPSS software version 17.0. Comparisons
between two groups were performed using unpaired t-tests. Linear
regression was performed to model the effect of age and/or sex on
all measured outcomes (pellet area change, histological grading
using the Bern score, and GAG content). P values of less than 0.05
were considered signiﬁcant.Results
Isolation and expansion of BMC
Mononuclear cells were obtained from all bone marrow speci-
mens. Cell colonies were visible from 8 to 10 days after initial
plating, at which time the cells were trypsinized for the ﬁrst time.
The average cell yield (% of cells that adhered to tissue-culture
plastic from the total number of mononuclear cells originally in
ﬂask) for males was 6.76 2.37% and that for females was
7.361.57%. No difference was observed based on donor age. The
ability of the isolated BMC to be expanded in culture over several
passages was investigated by plating them at 100 cells/cm2 fol-
lowed by trypsinization and counting every 7 days, for a total of 8
passages. All populations tested were capable of expansion up to
passage 8 [Fig. 1(a, b), numbers in legend indicate donor age]. From
the data presented in Fig. 1(a and b), the proliferation rate of BMC
was found to be independent of bone marrow donor age. The
expansion up to passage 8 results in 27.831.57 CPDs per initial
male BMC and 25.56 0.70 CPDs per initial female BMC [Fig. 1(c)].
No statistically signiﬁcant difference was observed between males
and females at all passages.Change in pellet area in response to TGFb1
Macroscopic images of the BMC pellets were taken after 21 days
of culture in CM in the presence or absence of TGFb1 [Fig. 2(a), top
row of Male BMC panel and Female BMC panel includes repre-
sentative pellets cultured in CM, and bottom row of each panelshows representative pellets cultured in CMþ TGFb1]. An increase
in pellet size was evident with the addition of TGFb1 to the CM for
all female BMC shown. The increase in pellet size with addition of
TGFb1 was less evident with increasing age in the male BMC pellets
shown [Fig. 2(a)]. Overall, with the exception of two male and two
female populations, all BMC tested increased in size with the
addition of TGFb1 to the CM [Fig. 2(b), *P< 0.05 vs CM]. No
difference in pellet area was observed between male and female
BMC [Fig. 2(b)]. The change in pellet area due to addition of TGFb1
to the CM was calculated by dividing the area of the pellets that
received TGFb1 by the area of the pellets that received CM only, for
every BMC donor. The change in pellet area for male BMC ranged
from 0.82 to 6.75 [Table II and Fig. 2(c)]. Female BMC were in the
range of 0.68 to 3.93, except for a 58-year-old female that displayed
an increase in pellet area of 9.96 0.47 [Table II and Fig. 2(c)].
Regression analysis of all data points indicated that neither sex nor
age signiﬁcantly affected the change in pellet area (age: P¼ 0.124,
sex: P¼ 0.856). However, when the analysis was performed on
male and female data separately, a signiﬁcant decrease in the
change in pellet area with increasing donor age was found in BMC
obtained from males [Fig. 2(c), R2¼ 0.253, *P¼ 0.02], but not from
females [Fig. 2(c), R2¼ 0.006, P¼ 0.746].Chondrogenesis
Toluidine blue staining of chondrogenic pellets provided infor-
mation on the extent of matrix formation and presence of sulfated
polysaccharides. Addition of TGFb1 to the CM increased chondroid
appearance in all populations tested when compared to those in
CM only (Fig. 3). However, cells with lacunae, indicative of
chondrocyte-like morphology, were more numerous in younger
(<30 years old) males than in elderly (>70 years old) males (Fig. 3,
arrows). A similar result of more chondrocyte-like cells in pellets
containing BMC from younger donors was also seen in the female
populations tested (Fig. 3, <30 years old compared to >70 years
old). Although some pellets containing BMC from elderly females
displayed chondrocyte-like cells and matrix formation, it was not
throughout the entire pellet, such as seen in the younger females.
Safranin O-Fast green staining was also investigated as a marker
of chondrogenic differentiation. Representative images of male and
female BMC pellets cultured in CM supplemented with TGFb1 are
shown in Fig. 4(a) (numbers in lower right hand corner of image
indicate the age of the donor). A reduction in the amount of
Safranin O-Fast green staining was observed with increasing donor
age in pellets containingmale BMC, while pellets containing female
BMC did not show a decrease with age. To systematically compare
all BMC populations tested for chondrogenesis, histological grading
was performed using the Bern score27. The histological grading of
Safranin O-Fast green stained pellets is based on the uniformity and
darkness of the staining, the amount of matrix formed, and the
morphology of the cells within the pellets. The Bern score ranges
from 0 to 9, with higher scores indicative of greater chondrogenic
differentiation. Addition of TGFb1 to the CM resulted in signiﬁ-
cantly higher Bern scores for both male and female BMC pellets
[Fig. 4(b), *P< 0.05 vs CM]. No signiﬁcant difference was observed
between the scores obtained with male BMC pellets compared to
female BMC pellets [Fig. 4(b)]. The effect of age on chondrogenesis
was also evaluated. A decrease in chondrogenesis with increasing
donor age was found when all BMC populations were analyzed
together [Fig. 4(c), R2¼ 0.170, *P¼ 0.007]. When the data was
separated by donor sex, the chondrogenesis was found to decrease
with increasing donor age in male BMC [Fig. 4(c), R2¼ 0.370,
*P¼ 0.003], but not in female BMC [Fig. 4(c), R2¼ 3106,
P¼ 0.994], which displayed a greater degree of variability within all
Fig. 1. CPDs of male and female BMC. (a) CPDs of male and (b) female BMC from passage 3 to 8. Numbers in the graph legend represent the age of the bone marrow donor. (c) The
average CPDs for male and female BMC from passage 3 to 8. n¼ 12 male BMC and 12 female BMC.
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tested in this study can be found in Table II.
Quantiﬁcation of GAG content per pellet provided a quantitative
measure of chondrogenic potential (Table II, Fig. 5). Analysis of all
data points revealed that the age of the bone marrow donor had
a signiﬁcant effect on GAG content (Fig. 5, R2¼ 0.150, *P¼ 0.016).
When this effect of donor age on GAG content was analyzed on data
acquired from male BMC and female BMC separately, it was
determined that an increase in age signiﬁcantly decreased GAG
content in male BMC (Fig. 5, R2¼ 0.304, *P¼ 0.018), but not in
female BMC (Fig. 5, R2¼ 0.010, P¼ 0.678).
Discussion
BMC isolated from bone marrow obtained from the distal femur
during orthopaedic surgery are similar to the BMC that would be
typically accessed during microfracture, a commonly performed
cartilage repair procedure. This study showed that femoral BMC can
be isolated and expanded from both men and women, regardless of
age. However, their degree of in vitro chondroid differentiation
following stimulation with TGFb1 varied by sex. Histological and
biochemical analysis indicated an age-related decline in chondroid
differentiationwith TGFb1 stimulation in males, but not in females.
Reports on the feasibility of BMC isolation and whether the cell
yield is associated with the sex and/or age of the donor are at times
conﬂicting. While some studies have reported a decrease in BMC
yield with increasing age21,23, others have not found such a rela-
tionship10,11,13,26. In the present study, BMC were isolated from allsamples obtained and the cell yield was similar for all samples,
regardless of sex and age. This indicates that it is feasible to isolate
femoral BMC for articular cartilage repair in both men and women,
regardless of age.
The ability of femoral BMC to proliferate for 8 passages suggests
that they have the potential to be expanded for autogenous appli-
cations. A decline in proliferation with age was not seen in our
study. The results suggest that BMC obtained from the femur of
older patients also have the capacity to be expanded for articular
cartilage repair and this is consistent with a recent study on femoral
BMC isolated from OA patients13. Our results are also in accordance
with those published on ﬁbrous synovium-, adipose synovium-,
and subcutaneous fat-derived mesenchymal cells, which did not
show a change in proliferation between young and elderly
donors29.
The increase in pellet area as a result of TGFb1 stimulation was
the ﬁrst indication that femoral BMC can respond to a chondrogenic
stimulus. By area measurement, it was determined that pellets
containing cells from oldermales did not show the same increase in
sizewith addition of TGFb1 to the CM, as younger male BMC pellets.
The increase in pellet area with TGFb1 stimulationwas not affected
by donor age in female BMC populations. Positive Safranin O-Fast
green staining suggests extracellular matrix (ECM) development
and is a strong indicator of chondrogenesis in vitro. None of the
BMC tested displayed positive Safranin O staining when cultured as
pellets in CM only, consistent with studies showing the need for
TGFb for BMC chondrogenesis7–10,15. Upon addition of TGFb1 to the
CM, many populations displayed varying intensities of positive
Fig. 2. Macroscopic appearance of BMC pellets and change in pellet area with addition of TGFb1. (a) Macroscopic images of representative male and female BMC pellets cultured in
CM (top row) or CMþ TGFb1 (bottom row) for 21 days. Numbers below the image indicate the age of the bone marrow donor. (b) Pellet area measured from the macroscopic images
of male and female BMC pellets cultured in CM and CMþ TGFb1 (10 ng/ml). *P< 0.05 compared to CM. (c) Change in pellet area due to addition of TGFb1 to CM for all populations
tested. Male BMC showed a decrease in pellet area change with increasing donor age (R2¼ 0.253, *P¼ 0.02), while females did not (R2¼ 0.006, P¼ 0.746). n¼ 21 male BMC and 20
female BMC.
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with the Bern score, wewere able to systematically compare all the
BMC populations tested in this study, and better deﬁne the vari-
ability seen. This allowed us to determine that male BMC showed
a decreased chondrogenic differentiation with increasing donor
age, while female BMC showed a similar mean for all age groups.
Quantitative measurement of GAG content in pellets further
conﬁrmed that a decreased ability to undergo chondrogenesis with
increasing age was found to occur in male BMC, but not in female
BMC. These results suggest that male BMC may have a diminished
responsiveness to TGFb1 as age increases. A similar ﬁnding has
been reported in human chondrocytes, where there was a decline
in growth factor responsiveness, measured by proliferation rate,
with increasing donor age30. Another interesting ﬁnding is that
some populations of BMC isolated from older females undergoing
surgery for joint replacement stained highly for Safranin O and had
high GAG content per pellet, suggesting that female BMC with
a high potential for chondrogenesis may be isolated from elderly
females, regardless of their disease state. This ﬁnding indicates that
BMC therapy could potentially be applied in OA.The effect of age on chondrogenesis has been previously
reported with conﬂicting results11,13,31–34. While an age-related
decline in chondrogenesis has been reported for rat BMC31, for
undifferentiated BMC in the periosteum32, for BMC isolated from
the iliac crest of normal donors34, and for human chondrocytes33,
BMC obtained from the open femur shaft of OA patients undergoing
hip replacement were found to be independent of age13. In
comparing our results to these previous studies, it should be noted
that all results, including our own, indicated that BMC stimulated
with a chondrogenic factor, such as TGFb1, displayed some degree
of chondrogenesis. Our study was designed to analyze a wide range
of ages, with a particular interest in the younger patient population,
since it has been reported that there is an age threshold between 30
and 40 years of age where the success of microfracture decreases6.
For this reason, the current study contains many BMC from donors
under the age of 40, in addition to BMC from older males, and this
allowed us to better determine the effect of age on chondrogenesis.
As well, separating the data by the sex of the donor, using the Bern
histological grading system, and a quantitative measure such as
GAG content, provided a more stringent comparison between the
Table II
Data for change in pellet area and for Bern score and GAG content of pellets cultured in CMþ TGFb1 for each BMC population
Age Change in pellet area Bern score GAG content/pellet (mg) Age Change in pellet area Bern score GAG content/pellet (mg)
Male 16 2.04 0.37 6.3 0.9 N/D Female 20 1.22 0.08 3 2 0.31 0.10
18 2.19 0.13 7.3 0.7 46.74 22 2.85 0.44 7 1 33.95 0.56
19 6.75 0.14 7 0 27.23 4.63 31 1.55 0.27 3.3 0.9 15.91 0.26
22 3.62 0.05 9 0 28.78 0.46 33 1.91 0.07 8 1 15.7 1.50
22 3.50 0.31 4.5 0.5 24.21 1.55 38 1.53 0.12 3.3 0.7 27.13 0.86
23 1.84 0.19 8.5 0.5 13.13 0.63 40 1.50 0.03 4 0 1.41 0.06
24 2.65 0.69 7 1 9.47 0.35 49 2.62 0.07 6 0 26.37 1.25
25 6.12 0.31 9 0 25.30 1.66 50 1.81 0.52 2.3 0.9 0.91 0.11
28 2.90 0.20 8 0 48.54 5.42 51 1.45 0.15 4.7 0.3 34.3 0.38
28 4.00 0.08 7.7 0.7 46.14 9.38 58 9.96 0.47 8 0 19.43 3.37
28 1.10 0.08 2.5 0.5 N/D 59 0.68 0.02 4.5 0.5 2.05 0.39
32 0.82 0.19 4.5 0.5 14.64 1.10 62 1.39 0.04 2 0 4.73 1.18
33 3.87 0.12 4.7 0.3 19.76 0.46 63 2.24 0.01 7.7 0.3 54.86 2.80
34 2.44 0.08 5 0.6 22.63 5.02 66 3.93 0.08 7.7 0.7 10.7
48 1.92 0.18 6 0 33.34 2.69 66 0.83 0.09 4.3 0.3 2.29 0.20
53 2.90 0.15 7.7 0.3 25.67 3.10 68 1.38 0.05 3 0 0.58 0.07
59 1.55 0.07 4.5 0.5 1.69 0.06 68 2.89 0.18 4.3 0.3 16.07 7.78
70 0.86 0.05 3 0 13.36 1.41 70 1.73 0.14 2.5 0.5 1.89 0.25
80 1.20 0.05 2.3 0.3 1.67 0.14 72 1.75 0.02 6 0.6 0.17 0.14
81 1.31 0.07 2 1 N/D 77 1.72 0.19 5 0 30.04 1.08
82 1.62 0.27 5.3 0.7 10.89 2.83
Mean 39.3 2.63 5.8 22.96 Mean 53.1 2.25 4.8 14.94
S.E.M. 4.9 0.35 0.5 3.35 S.E.M. 3.84 0.44 0.4 3.44
All data are reported as the mean S.E.M.
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age-related differences in the chondrogenesis of femoral BMC
when stimulated with TGFb1.
A variety of growth factors have been reported to induce
chondrogenesis in BMC. Members from the TGFb family have been
used extensively, with early reports employing TGFb18,10 or
TGFb39,15 in addition to dexamethasone to promote chondro-
genesis in BMC. Bone morphogenetic proteins (BMPs), insulin
growth factor-1 (IGF-1), and ﬁbroblast growth factor-2 (FGF-2)
have also been used either individually or in combination to induce
chondrogenesis in BMC35–39. All have induced some degree of
chondroid differentiation, although not necessarily to the same
extent36,38. The current study has focused on the response of maleFig. 3. Toluidine blue staining of BMC pellets after 21 days of culture. Representative images
>70 years old cultured in CM (top row) or CMþ TGFb1 (bottom row). A greater number of
chondrocyte-like cells could be found in elderly females, but they did not span the entire pand female BMC of various ages to TGFb1. Age- and sex-related
differences in the chondrogenesis of BMC stimulated with other
proven growth factors may lead to different outcomes, and is an
interesting area to investigate in future studies.
In the case of BMC-based therapies that require expansion ex
vivo, it will be important to promote the differentiation potential of
all populations, including those with lower observed chondro-
genesis to standard chondrogenic stimuli, such as TGFb1. A
potential approach to overcome the decreased differentiation
ability of certain BMC populations is the addition of growth factors
during cell expansion. This has previously been shown with
chondrocytes and BMC33,40,41. Addition of FGF-2 to the culture
medium of human trabecular bone mesenchymal stromal cellsof Toluidine blue staining in pellets containing male or female BMC< 30 years old and
chondrocyte-like cells (arrows) were present in younger males than elderly males. The
ellet.
Fig. 4. Safranin O-Fast green staining of male and female BMC pellets and histological grading. (a) Representative images of Safranin O-Fast green staining of pellets containing male
or female BMC of increasing donor age that were cultured in CMþ TGFb1 for 21 days. (b) Histological grading of male and female BMC pellets cultured in CM or CMþ TGFb1 using
the Bern score. *P< 0.05 compared to CM. (c) Bern score for all populations tested. Male BMC showed a declining Bern score with increasing donor age (R2¼ 0.370, *P¼ 0.003),
while females did not (R2¼ 3106, P¼ 0.994). n¼ 21 male BMC and 20 female BMC.
K.A. Payne et al. / Osteoarthritis and Cartilage 18 (2010) 705–713 711from elderly patients led to better osteogenic and adipogenic
differentiation potential, yet it did not consistently improve chon-
drogenesis in all populations tested40. Barbero et al. also observed
that expansion of chondrocytes with a combination of TGFb1, FGF-2
and platelet-derived growth factor-BB (PDGF-BB) improved the
chondrogenic ability of chondrocytes from younger donors, but not
donors over the age of 4033. Further studies with similar or different
combinations of growth factors are thus warranted to help improve
the chondrogenesis of cells with lower differentiation potential.Fig. 5. GAG quantiﬁcation of male and female BMC pellets cultured in CMþ TGFb1 for
21 days. GAG content per pellet (mg) for all populations tested. Male BMC showed
a declining GAG content with increasing donor age (R2¼ 0.304, *P¼ 0.018), while
females did not (R2¼ 0.010, P¼ 0.678). n¼ 18 male BMC and 20 female BMC.Overall, this study demonstrated that femoral BMC obtained
during orthopaedic surgery are a promising cell source for articular
cartilage repair. It indicated that there exists an age-related loss in
the chondrogenic potential of male femoral BMC, but not in female
femoral BMC. The pellet culture system used in this study is
a controlled environment, where TGFb1 was the main chondro-
genic factor. This suggests that with increasing age, the ability of
male BMC to respond to TGFb1 may be impaired. Finding ways to
stimulate cartilage repair in older males may require bypassing the
TGFb1 pathway by using other proven chondrogenic growth
factors. As well, within the same age group, there were populations
that did not undergo chondrogenesis to the same extent. This
variability between individuals may explain the different clinical
outcomes seenwith the microfracture technique. Our ﬁndings thus
justify further studies on the effect of cell sex and age on chon-
drogenesis and on the identiﬁcation of the underlying mechanisms
responsible for the differences seen in the BMC that are low-TGFb1
responders vs the BMC that are high-TGFb1 responders. Under-
standing the mechanisms for these observed differences will
contribute to improved clinical use of autologous human BMC for
articular cartilage repair, and may lead to the development of
customized age- or sex-based treatments to delay or prevent the
onset of OA.
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